Page 122 - Haematologica May 2022

J. Gao et al.
334.
8. Winter GE, Mayer A, Buckley DL, et al. BET
bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol Cell. 2017; 67(1):5-18.
9. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018; 17(5):353-377.
10. Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in devel- opment and disease. Genes Dev. 2011; 25(7):661-672.
11. He N, Liu M, Hsu J, et al. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coor- dinated activation of HIV-1 transcription. Mol Cell. 2010; 38(3):428-438.
12. Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super- enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014; 159(5): 1126-1139.
13. Christensen CL, Kwiatkowski N, Abraham BJ, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014; 26(6):909-922.
14. Wang Y, Zhang T, Kwiatkowski N, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015; 163(1):174-186.
15. Pelish HE, Liau BB, Nitulescu II, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015;526(7572):273-276.
16. Zhao X, Ren Y, Lawlor M, et al. BCL2
17. 18.
19.
amplicon loss and transcriptional remodel- ing drives ABT-199 resistance in B cell lym- phoma models. Cancer Cell. 2019;35(5):752- 766.
Lui GYL, Grandori C, Kemp CJ. CDK12: an emerging therapeutic target for cancer. J Clin Pathol. 2018;71(11):957-962.
Dubbury SJ, Boutz PL, Sharp PA. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature. 2018; 564(7734):141-145.
Krajewska M, Dries R, Grassetti AV, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019;10(1):1757.
25. Silva A, Jacobson T, Meads M, et al. An organotypic high throughput system for characterization of drug sensitivity of pri- mary multiple myeloma cells. J Vis Exp. 2015;(101):e53070.
26. Silva A, Silva MC, Sudalagunta P, et al. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Res. 2017;77(12):3336-3351.
27. Zhao X, Lwin T, Silva A, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017; 8:14920.
28. Wang J, Ye Q, She QB. New insights into 4E- BP1-regulated translation in cancer progres- sion and metastasis. Cancer Cell Microenviron. 2014;1(5):e331.
29. Gao Y, Zhang T, Terai H, et al. Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors. Cell Chem Biol. 2018;25(2):135-142.
30.Olson CM, Liang Y, Leggett A, et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phe- notype. Cell Chem Biol. 2019;26(6):792-803.
31. Cihalova D, Staud F, Ceckova M. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS- 032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to over- come multidrug resistance in vitro. Cancer Chemother Pharmacol. 2015;76(1):105- 116.
32.Zhang P, de Gooijer MC, Buil LC, et al. ABCB1 and ABCG2 restrict the brain pene- tration of a panel of novel EZH2-Inhibitors. Int J Cancer. 2015;137(8):2007-2018.
20. Iniguez AB, Stolte B, Wang EJ, et al. EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018;33(2):202-216.
21. Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-neg- ative breast cancer. Cell Rep. 2016; 17(9):2367-2381.
22.Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
23.Campaner S, Amati B. Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div. 2012;7(1):6.
24. Rohban S, Campaner S. Myc induced replicative stress response: how to cope with it and exploit it. Biochim Biophys Acta. 2015;1849(5):517-524
1130
haematologica | 2022; 107(5)